NA
HRMY icon

Navellier & Associates’s Harmony Biosciences HRMY Stock Holding History

Navellier & Associates’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-5,992
Closed -$211K – 325
2023
Q2 		$211K Sell
5,992
-249
-4% -$8.6K 0.04% 247
2023
Q1 		$204K Sell
6,241
-172
-3% -$7.83K 0.04% 256
2022
Q4 		$353K Sell
6,413
-613
-9% -$33.7K 0.07% 202
2022
Q3 		$311K Buy
+7,026
New +$343K 0.07% 214

Other funds holding HRMY

VM
Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Navellier & Associates's HRMY Position: Q3 2023 in Review

Navellier & Associates sold out of Harmony Biosciences (HRMY) in Q3 2023, closing a stake of 5,992 shares — an estimated $211K sold.

Navellier & Associates first reported a position in HRMY in Q3 2022 and held it in 4 quarters. The position peaked at $353K in Q4 2022. 204 funds tracked by Wall St. Rank hold HRMY as of Q3 2023.

  • Navellier & Associates reported no remaining Harmony Biosciences position as of Q3 2023 after selling out during the quarter.
  • Navellier & Associates sold 5,992 Harmony Biosciences shares in Q3 2023, an estimated $211K.
  • Navellier & Associates first reported a position in Harmony Biosciences in Q3 2022 and held it in 4 quarters.
  • Navellier & Associates's Harmony Biosciences position peaked at $353K in Q4 2022.
  • 204 funds tracked by Wall St. Rank held Harmony Biosciences as of Q3 2023.

Based on Navellier & Associates's 13F filing for Q3 2023, filed 9 Nov 2023.